New EU API rules: No deal for Singapore on equivalency
This article was originally published in SRA
The European Commission has rejected Singapore's application to be included in the list of third countries that will be exempt from a provision of the EU Falsified Medicines Directive requiring them to issue written confirmations to local manufacturers of active pharmaceutical ingredients (APIs) who wish to export their products to the EU1.
You may also be interested in...
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.